Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Vistagen Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $44.74M, down 8.9% year over year. For fiscal 2026 it was $54.97M, up 39.6% from the year before. Over ten years it grew 30.2% a year on average. The highest annual figure on record is $54.97M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $54.97M | +39.6% |
| FY2025 | Mar 31, 2025 | $39.38M | +96.7% |
| FY2024 | Mar 31, 2024 | $20.02M | -54.9% |
| FY2023 | Mar 31, 2023 | $44.38M | +25.3% |
| FY2022 | Mar 31, 2022 | $35.41M | +196.9% |
| FY2021 | Mar 31, 2021 | $11.93M | -10.8% |
| FY2020 | Mar 31, 2020 | $13.37M | -21.8% |
| FY2019 | Mar 31, 2019 | $17.10M | +120.3% |
| FY2018 | Mar 31, 2018 | $7.76M | +49.2% |
| FY2017 | Mar 31, 2017 | $5.20M | +32.4% |
| FY2016 | Mar 31, 2016 | $3.93M | +61.6% |
| FY2015 | Mar 31, 2015 | $2.43M | -1.9% |
| FY2014 | Mar 31, 2014 | $2.48M | -27.7% |
| FY2013 | Mar 31, 2013 | $3.43M | -36.3% |
| FY2012 | Mar 31, 2012 | $5.39M | +46.5% |
| FY2011 | Mar 31, 2011 | $3.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $6.55M | -58.8% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $10.91M | -6.6% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $13.06M | +28.0% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $14.22M | +25.8% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $15.92M | +55.8% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $11.68M | +52.7% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $10.21M | +37.3% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $11.31M | +149.2% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $10.22M | +165.3% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $7.65M | +82.2% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $7.44M | -20.4% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $4.54M | -33.8% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $3.85M | -70.1% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $4.20M | -72.6% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $9.34M | -23.7% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $6.85M | -11.9% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $12.89M | +29.8% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $15.29M | +180.2% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $12.23M | +150.1% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $7.78M | +122.5% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $9.94M | +321.4% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $5.46M | +36286.7% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $4.89M | +165.8% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $3.50M | +16.0% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $2.36M | -43.9% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $15.00K | -99.7% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $1.84M | -51.0% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $3.02M | -43.5% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $4.21M | -20.1% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $4.31M | +57.2% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $3.76M | +42.5% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $5.34M | +233.0% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $5.26M | +116.8% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $2.74M | +150.4% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $2.64M | +127.2% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $1.60M | -0.6% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $2.43M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $1.10M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $1.16M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $1.61M | – |
See a number that looks wrong?